Sign in Subscribe
Diabetes therapy

Comparative Analysis of Cost-Utility: Chiglitazar Vs. Sitagliptin In Patients With Type 2 Diabetes In China

Strategic Insights

— 2 min read

A new study published in the Journal of Diabetes and its Complications has compared the long-term clinical and economic outcomes of chiglitazar and sitagliptin in patients with type 2 diabetes mellitus (T2DM) in China. The research, conducted by a team of investigators from Shenzhen University, aimed to evaluate the cost-effectiveness of these two treatments from a healthcare system perspective. According to the study, chiglitazar showed dual therapeutic benefits for glycemic control and lipid management in T2DM, but comprehensive pharmacoeconomic evaluations comparing it with conventional therapies like sitagliptin were unavailable for China's healthcare system.

Key Takeaways:

  • The study conducted a comparative cost-utility analysis of chiglitazar versus sitagliptin for T2DM treatment in China, evaluating long-term clinical and economic outcomes from a healthcare system perspective.
  • Data on patient demographics and post-treatment effects were collected from a double-blind, phase 3, randomized controlled trial conducted in China, which involved 40-year simulation and estimated an optimal annual cost for sitagliptin in scenario analyses.
  • The life expectancy results showed comparable results among treatments: 14.93 years for chiglitazar 32 mg, 14.94 years for chiglitazar 48 mg, and 14.93 years for sitagliptin 100 mg.
  • The corresponding quality-adjusted life years (QALYs) reached 12.82, 12.83, and 12.81, respectively.
  • Total accumulated costs over the simulation period were $44,241.09 (chiglitazar 32 mg), $45,044.25 (chiglitazar 48 mg), and $44,821.45 (sitagliptin 100 mg).
  • Long-term economic evaluation revealed that chiglitazar 32 mg provided the optimal cost-effectiveness, whereas sitagliptin 100 mg was the least economically advantageous option.
  • One-way and probabilistic sensitivity analyses confirmed the robustness of these findings, and scenario analysis showed that sitagliptin 100 mg only becomes cost-effective when its annual cost is reduced by at least 42.33% compared to chiglitazar 32 mg.
  • The research concluded that chiglitazar demonstrates significantly better long-term health outcomes and cost-effectiveness relative to sitagliptin for T2DM management.

Statistics:

  • Life expectancy:

+ Chiglitazar 32 mg: 14.93 years

+ Chiglitazar 48 mg: 14.94 years

+ Sitagliptin 100 mg: 14.93 years

  • Quality-adjusted life years (QALYs):

+ Chiglitazar 32 mg: 12.82

+ Chiglitazar 48 mg: 12.83

+ Sitagliptin 100 mg: 12.81

  • Total accumulated costs:

+ Chiglitazar 32 mg: $44,241.09

+ Chiglitazar 48 mg: $45,044.25

+ Sitagliptin 100 mg: $44,821.45

  • Optimal annual cost for sitagliptin: at least 42.33% reduction compared to chiglitazar 32 mg

Sources:

  • A Comparative Analysis of Cost-utility: Chiglitazar Vs. Sitagliptin In Patients With Type 2 Diabetes In China. Journal of Diabetes and its Complications, 2025;39(11).
  • NewsRx. Studies from Shenzhen University Describe New Findings in Type 2 Diabetes (A Comparative Analysis of Cost-utility: Chiglitazar Vs. Sitagliptin In Patients With Type 2 Diabetes In China). Diabetes Week. November 3, 2025; p 454.

Read more